- An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacy
- SYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in mUC and 43% ORR and 86% DCR in cervical cancer to date at doses ≥ 1.2mg/Kg
- No dose limiting toxicities (DLTs) have been observed to date in doses up to and including 4.5 mg/Kg (cohort 7)
- Three cases of skin rash (including one grade 3) and one case of grade 1 neuropathy seen to date; all were resolved
- Early PK data demonstrate consistently lower levels of free MMAE than enfortumab vedotin across all doses in study including 4.5 mg/Kg
https://www.globenewswire.com/news-release/2024/06/01/2891822/0/en/SYS6002-CRB-701-A-Next-Generation-Nectin-4-Targeting-Antibody-Drug-Conjugate-Continues-to-Demonstrate-Encouraging-Safety-and-Efficacy-Observed-in-Patients-with-Nectin-4-Positive-Tu.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.